Analysts Issue Forecasts for ABEO Q3 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Zacks Small Cap issued their Q3 2025 EPS estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Monday, March 24th. Zacks Small Cap analyst D. Bautz anticipates that the biopharmaceutical company will earn ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday. Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target for the company. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $5.04 on Thursday. The stock has a market capitalization of $219.09 million, a price-to-earnings ratio of -1.87 and a beta of 1.79. The business’s 50 day moving average is $5.42 and its two-hundred day moving average is $5.81. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $8.45. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. grew its position in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after purchasing an additional 652,366 shares during the last quarter. Western Standard LLC lifted its stake in Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares in the last quarter. 683 Capital Management LLC grew its holdings in Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after buying an additional 116,845 shares during the last quarter. Citigroup Inc. increased its position in Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after buying an additional 56,332 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after acquiring an additional 83,050 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.